Publications for Kathleen Mulligan kathleen.mulligan@tu.edu

Gugliucci, A., Lustig, R. H., Caccavello, R., Erkin-Cakmak, A., Noworolski, S. M., Mulligan, K., . . . Schwarz, J. M. (2016). Short-term isocaloric fructose restriction lowers apoC-III levels and yields less atherogenic lipoprotein profiles in children with obesity and metabolic syndrome. Atherosclerosis, 253, 171-177. doi:10.1016/j.atherosclerosis.2016.06.048

Lustig, R. H., Mulligan, K., Noworolski, S. M., Tai, V. W., Wen, M. J., . . . Gugliucci, A., & Schwarz, J. M. (2016). Isocaloric fructose restriction and metabolic improvement in children with obesity and metabolic syndrome. Obesity, 24(2), 453-460. doi:10.1002/oby.21371

Schwarz, J. M., Noworolski, S. M., Wen, M. J., Jones, G. M., Sinclair, E., Velasco-Alin, M., Gugliucci, A., . . . Mulligan, K. (2015). Isocaloric fructose restriction for 10 days reduces hepatic de novo lipogenesis and liver fat in obese Latino and African American children [Supplemental material]. Endocrine Reviews, 36(2). This material can be found here.

Campos, G. M., Rabl, C., Havel, P. J., Rao, M., Schwarz, J. M., Schambelan, M., & Mulligan, K. (2014). Changes in post-prandial glucose and pancreatic hormones, and steady-state insulin and free fatty acids after gastric bypass surgery. Surgery for Obesity and Related Diseases, 10(1), 1-8. doi:10.1016/j.soard.2013.07.010

Jones, G. M., Sinclair, E., Pullinger, C., Caccavello, R., . . . Mulligan, K., Gugliucci, A., Schwarz, J. M. (2014). An immuno-affinity method to separate chylomicrons from VLDL and to ascertain the conversion of sugar to fat by de novo lipogenesis in human intestine. Diabetes, 63(Suppl. 1A), LB58. This material can be found here.

Rabl, C., Rao, C. M. N., Schwarz, J. M., Mulligan, K., Campos, G. M. (2014). Thermogenic changes after gastric bypass, adjustable gastric banding or diet alone. Surgery, 156(4), 806-813. doi:10.1016/j.surg.2014.06.070

Rao, M., Mulligan, K., Tai, V., Wen, M., Dyachenko, A., Weinberg, M., & Schambelan, M. (2010). Effects of insulin-like growth factor (IGF)-I/IGF-binding protein-3 treatment on glucose metabolism and fat distribution in human immunodeficiency virus-infected patients with abdominal obesity and insulin resistance. Journal of Clinical Endocrinology and Metabolism, 95(9), 4361-4366. PMCID:PMC2936071

Mulligan, K., Khatami, H., Schwarz, J. M., Sakkas, G. K., DePaoli, A. M., Tai, V. W., . . . Schambelan, M. (2009). The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia. Journal of Clinical Endocrinology and Metabolism, 94(4):1137-1144. doi: 10.1210/jc.2008-1588 This material can be found here.